Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Health Yuan enters the analgesia track, Nav1.8 inhibitor expands the synergistic boundary of chronic disease ecology
Published Time：
2025-03-26
As innovative drugs accelerate towards mechanism upgrades and precise adaptation expansion, HealthGen Pharma has begun to lay out diversified innovation fields beyond its main line of respiratory disease treatment. The company's research and development project targeting Nav1.8 sodium channel inhibitors for pain relief marks a significant extension in its chronic disease treatment chain, and also reflects its path choice of continuously deepening its multi-pipeline synergy strategy.
Pain management is moving towards a focus on both policy attention and mechanism innovation.
The value of non-opioid pathways is becoming increasingly apparent.
According to WHO and industry data, over 30% of the global population suffers from chronic pain to varying degrees. Pain has become the third largest public health burden after cardiovascular and cerebrovascular diseases and tumors. Traditional opioid drugs face challenges such as addiction, tolerance, and tightening regulations, and the limitations of existing treatments such as NSAIDs in managing moderate to severe pain are also becoming increasingly apparent, driving the global research focus towards non-opioid targets.
Nav1.8, as an important sodium channel in the peripheral nervous system for pain signal transduction, has characteristics such as high mechanism selectivity, no central nervous system impact, and low dependence risk. It is considered a new generation of targets for pain relief treatment. In 2025, the first non-opioid analgesic drug based on the Nav1.8 target, Journavx, was approved in the United States, breaking the 20-year stagnation of mechanism innovation in this field, and providing a path reference and regulatory window for the subsequent development of similar products.
Extension of the respiratory system mainline.
Central projects strengthen the synergistic value of chronic diseases.
For a long time, HealthGen has focused on chronic respiratory diseases as its core business segment, and has built a relatively systematic product structure in the fields of inhalation preparations, biological antibody drugs, and oral anti-inflammatory drugs. In clinical practice, some chronic respiratory diseases, including COPD, asthma, and lung cancer patients, often have concomitant long-term inflammatory neuropathic pain, postoperative pain, and other complications, and there is a long-standing gap in pain management treatment.
The continuous advancement of the Nav1.8 inhibitor project not only constitutes an important reinforcement of HealthGen's innovative pipeline, but also forms a practical synergy between "respiration + analgesia" in the chronic disease management system, and is expected to play a more systematic synergistic role in the whole-cycle treatment plan for chronic diseases.
Steady progress of the pipeline, obvious window period advantage.
Currently, HealthGen's Nav1.8 project, after pre-clinical active molecule screening, efficacy evaluation, and toxicology research, is in the phase I clinical stage, focusing on safety research. According to incomplete statistics, only a very small number of pharmaceutical companies internationally have completed early clinical exploration. Under the current relatively relaxed competitive landscape and with international pathways already available for reference, the company is expected to gain a first-mover advantage.
According to Evaluate Pharma's prediction, the global non-opioid analgesic market will reach over US$15 billion in 2028, and targets such as Nav1.8 are expected to become a major source of incremental growth. Compared with the traditional opioid pathway, these drugs have higher acceptance in medical insurance negotiations, payment mechanism construction, and public health policies, and are also expected to achieve faster market penetration and commercial validation.
Formation of a diversified innovation structure, enhancing valuation resilience.
HealthGen has continuously promoted the "mechanism innovation + multi-indication coverage" strategy in recent years, gradually shifting from a single-track model focusing on the respiratory system to a diversified synergistic direction such as "anti-infection + respiration + analgesia." The introduction of Nav1.8 inhibitors further enhances the company's innovative drug pipeline reserves. From a financial and capital market perspective, although new mechanism projects have uncertainties such as long R&D cycles and great technological challenges, once they enter the late clinical stage, they have a strong valuation amplification effect. For HealthGen, whose current valuation system is still mainly based on the respiratory sector, the Nav1.8 project is expected to become its next "R&D-valuation" coupled growth driver.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.